Why Traditional Terminal Value Thinking Breaks Down in Life Sciences

The Question Investors Keep Asking

A question that investors continue to evaluate for commercial-stage life sciences companies is one that shifts away from clinical data, market opportunity, and competitive positioning.

Instead, it focuses on a much more fundamental question: How can they think about terminal value when the target company's most important asset eventually loses patent protection?

It is a simple question on the surface. Yet it sits at the heart of many life sciences investment decisions.

In traditional industries, terminal value is often calculated using familiar approaches. Analysts project cash flows, apply a perpetual growth assumption or an exit multiple, and arrive at a valuation. While the mechanics can become sophisticated, the underlying assumption remains relatively straightforward: the business continues to operate and generate value indefinitely.

Commercial-stage life sciences rarely works that way.

For many pharmaceutical, biotechnology, diagnostics, and medical technology businesses, value creation is heavily influenced by intellectual property protection, exclusivity periods, regulatory milestones, and competitive dynamics. The timing of patent expiration can fundamentally reshape the economics of an investment. As a result, investors must think differently.

This article outlines how investors and strategic buyers can approach terminal value in life sciences transactions and why cash flow durability often matters more than patent duration alone.

The Problem With Traditional Terminal Value Models

Traditional valuation methodologies implicitly assume that a company can continue generating and growing cash flows indefinitely.

That assumption becomes problematic when evaluating a business built around a single therapeutic asset or a limited portfolio of protected products.

Eventually, patents expire.

When exclusivity is lost, competitors enter the market. Generic or biosimilar alternatives emerge. Pricing pressure increases. Market share can erode rapidly. The result is that future cash flows often do not resemble the historical cash flows that supported the original investment case.

This creates a challenge. A terminal value calculation based solely on current earnings or a generic industry multiple may significantly overstate or understate the true economic value of the business.

The key question therefore becomes: What happens to cash flows before and after exclusivity ends?

Two Companies, One Patent Expiration Date

Consider two hypothetical companies. Both companies have their primary patents expiring in 2040. At first glance, they appear similar. Yet their valuation profiles could be dramatically different.

Company A

Company A has:

• Strong physician adoption

• Clear clinical differentiation

• Favorable reimbursement

• Limited competitive threats

• High switching costs

When patent protection expires, some market share erosion occurs, but a meaningful portion of revenue remains durable.

Company B

Company B has:

• Limited differentiation

• Aggressive competitors

• Significant pricing pressure

• Low switching barriers

• Weak market positioning

Once exclusivity ends, revenue declines rapidly and margins compress significantly. Both companies lose exclusivity in the same year. Both companies operate in the same market.

Yet one may be worth several times more than the other.

The difference is not the patent date. The difference is the expected cash flow profile surrounding that patent date.

The Five Drivers of Terminal Value

1. Remaining Exclusivity

Patent life matters. However, investors often focus too narrowly on the expiration date itself.

The more important question is how much value can be created during the exclusivity period and whether additional protections exist through formulation patents, manufacturing know-how, data exclusivity, or other barriers to entry.

The duration of protection influences the investment horizon, but it does not determine value on its own.

2. Revenue Durability

Not all revenue streams are equally resilient. Investors should evaluate whether customers, physicians, payers, or healthcare systems are likely to continue supporting the product over time.

Strong adoption patterns and embedded clinical utility often create more durable cash flows than headline revenue figures alone suggest.

3. Competitive Insulation

Future competitors are often the largest threat to terminal value.

A company may enjoy a favorable market position today, but investors must assess what happens when new therapies, technologies, or business models emerge.

Competitive resilience is often more important than current market share.

4. Market Expansion Potential

Some assets continue creating value long before patent expiry because they gain access to additional patient populations, geographies, indications, or adjacent markets.

Investors should assess not only the existing opportunity but also the pathways for future expansion.

5. Strategic Relevance

A company's value is ultimately determined by what future buyers are willing to pay. Strategic acquirers may value assets differently than financial sponsors.

An asset that fills a portfolio gap, strengthens a therapeutic franchise, or addresses a future revenue challenge may command a premium that exceeds what standalone financial metrics would suggest.

Understanding who the likely future buyer is often provides important insight into terminal value.

How We Think About Terminal Value

At ClarityNorth Partners, we rarely begin with the question: "What multiple should this company trade at?"

Instead, we start with a different question: What must be true for future cash flows to materialize as expected?

This shifts the discussion away from valuation mechanics and toward the underlying drivers of value.

Can physicians continue adopting the product?

Will reimbursement remain supportive?

Can the company maintain differentiation?

How vulnerable is the business to competitive disruption?

Will management successfully execute its commercialization strategy?

The answers to these questions ultimately determine whether projected cash flows are realistic and whether terminal value assumptions are defensible.

Terminal Value Is Ultimately a Cash Flow Question

Life sciences investing often appears highly scientific. Clinical data, regulatory pathways, and technological innovation dominate discussions. Yet at its core, valuation remains remarkably simple.

Investors are underwriting future cash flows. Patents, competitive dynamics, physician behavior, reimbursement decisions, and management execution all matter because they influence the durability and magnitude of those future cash flows.

The most successful investors recognize that terminal value is not defined by a patent expiration date. It is defined by what happens before and after that date. Understanding that distinction often separates strong investments from disappointing ones.

Get in Touch

Disclaimer:The information provided in this article is for general informational purposes only and does not constitute legal, financial, or professional advice. ClarityNorth Partners makes no representations or warranties of any kind regarding the accuracy, completeness, or suitability of the information. Readers should consult with their advisors before making any business decisions based on this content.

© ClarityNorth Partners 2026. All rights reserved